Clinuvel Pharmaceuticals (CUV) H2 2024 earnings summary

Executive summary

• Achieved record financial results for FY2024, with total revenues rising 15% year-over-year to $95.3 million and net profit after tax increasing 16% to $35.6 million, reflecting successful execution of long-term strategy and disciplined cost management.

• Marked eight consecutive years of profitability and seventh consecutive annual dividend, with a focus on diversification, new jurisdictions, and pipeline development.

• Expanded operational capabilities with new hires in key roles and progress in pharmaceutical and photocosmetic segments.

Financial highlights

• Total revenues, interest, and other income reached $95.3 million, up 15% year-over-year, driven by demand for SCENESSE® in Europe and North America.

• Net profit before tax rose 11% to $50.7 million; net profit after tax up 16% to $35.6 million.

• Cash reserves increased 17% to $183.9 million, supporting self-financed diversification plans.

• Basic EPS rose to $0.72, up 15% year-over-year; net tangible assets per share increased 22% to $4.02.

• Fully franked dividend of $0.05 per share declared for the seventh consecutive year.

Outlook and guidance

• No formal guidance provided, but management highlighted strong cash reserves and optionality for both organic and inorganic growth.

• Next three-year expenses and growth plan to be finalized in Q4 2024 and revealed in H1 2025.

• Ongoing investment in R&D, new formulations, and product indications, with continued disciplined capital deployment.

• Intends to maintain financial performance and integrate in-house manufacturing.